

4 April 2017

**Deltex Medical Group plc**  
("Deltex Medical" or "the Company")

**Exercise of Options**

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM") announces that it has issued 110,000 new Ordinary Shares of 1 pence each in the capital of the Company ("Ordinary Shares") in connection with the exercise of options by a former employee granted under the Company's 2003 share option scheme. The options had an exercise price of 1 pence per share and the notice of exercise was received on 31 March 2017.

Application has been made for the 110,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on 10 April 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 296,741,733. The Company does not hold any shares in treasury. Accordingly, the figure of 296,741,733 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

**For further information, please contact:-**

**Deltex Medical Group plc**

01243 774 837  
[investorinfo@deltexmedical.com](mailto:investorinfo@deltexmedical.com)

Nigel Keen, Chairman  
Ewan Phillips, Chief Executive  
Jonathan Shaw, Group Finance Director

**Nominated Adviser & Broker**  
**Arden Partners plc**

020 7614 5900

Chris Hardie

**Financial Public Relations**  
**IFC Advisory Ltd**

0203 053 8671

Tim Metcalfe  
Graham Herring  
Heather Armstrong

**Notes for Editors**

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

## **Company goal**

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.